K-Ras
K-Ras (KRAS) is a small GTPase that functions as a molecular switch within the RAS/MAPK signaling network, cycling between inactive GDP-bound and active GTP-bound states to regulate cell proliferation, differentiation, and survival[1][2]. Mechanistically, activated KRAS transduces signals from cell-surface receptors to downstream effectors, including the MAPK/ERK and PI3K/AKT pathways, thereby coordinating cellular growth and stress-response programs[1][3]. Oncogenic mutations impair GTP hydrolysis and maintain persistent KRAS signaling, resulting in sustained activation of proliferative pathways that contribute to tumor initiation, progression, and therapeutic resistance across multiple cancer types, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer[2][3][4]. In disease models, mutant KRAS also reshapes the tumor microenvironment through inflammatory and immune-regulatory signaling, further supporting tumor development and immune evasion[3][2]. Compared with the related RAS isoforms HRAS and NRAS, KRAS is the most frequently altered RAS family member in human cancer and accounts for the majority of oncogenic RAS mutations, highlighting its distinct biological and clinical importance[2][5]. For experimental applications, the development of mutation-selective inhibitors, especially KRAS^G12C^ inhibitors, has established a tractable platform for studying KRAS-dependent signaling and therapeutic resistance mechanisms, although resistance remains a major challenge for long-term clinical efficacy[2][5].
References:
- [1]. K-Ras gene information.
- [2]. Huang L, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. [Content Brief]
- [3]. Uniyal P, et al. KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy. Cancers (Basel). 2025 Feb 25;17(5):785. [Content Brief]
- [4]. Suda K, et al. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010 Mar;29(1):49-60. [Content Brief]
- [5]. Riedl JM, et al. Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell. 2026 Mar 9;44(3):471-497. [Content Brief]
-
K-Ras Related Products (283)
Related Products (283)
-
KRAS-IN-64
0 ImagesCat. No.: HY-189278KRAS-IN-64 is a KRAS inhibitor that inhibits KRAS translation by binding to and stabilizing the G-quadruplex in the 5'-UTR of KRAS mRNA, exhibits antiproliferative activity in KRAS-mutant cancer cells, and induces cell cycle arrest, non-apoptotic cell death, and PARP cleavage-mediated apoptosis (apoptosis). KRAS-IN-64 can be used for research on pancreatic cancer.
-
KRAS G12C inhibitor 43
0 ImagesCat. No.: HY-142945CAS No.: 2648808-69-7KRAS G12C inhibitor 43 (compound 59) is a potent KRAS G12C inhibitor. KRAS G12C inhibitor 43 shows antimigration and anti-proliferative activity with IC50s of 0.001-1 µM, >1 µM, >1 µM for H358, A549, HCC cells ,respectively.
-
KRAS G12C inhibitor 69
0 ImagesCat. No.: HY-170550KRAS G12C inhibitor 69 (Compound K09) is the inhibitor for mutant RAS protein KRASG12C with an IC50 of 4.36 nM. KRAS G12C inhibitor 69 inhibits the ERK phosphorylation in NCI-H358 and MIA-PACA-2 with an IC50 of 12 nM and 7 nM. KRAS G12C inhibitor 69 inhibits the proliferation of cancer cell NCI-H358 and MIA-PACA-2 with IC50 of 3.15 nM and 2.33 nM.
-
KRAS G12C-IN-79
0 ImagesCat. No.: HY-183645CAS No.: 3088522-27-1KRAS G12C-IN-79 is a KRASG12C inhibitor with an IC50 of 1.9 nM. KRAS G12C-IN-79 functionally inhibits the activity of the GDP-bound form of KRASG12C. KRAS G12C-IN-79 can be used for the research of nonsmall cell lung cancer, colon cancer, pancreatic cancer.
-
KRAS-IN-51
0 ImagesCat. No.: HY-186024CAS No.: 3076211-50-9KRAS-IN-51 (Compound 597a) is a KRas G12V inhibitor, with its IC50 for KRas G12V being 2.9 nM; KD values are 17 (at 20°C) and 68 (at 37°C) nM. KRAS-IN-51 inhibits the phosphorylation of pERK. KRAS-IN-51 has anti-proliferative activity against SW620 and MIAPaCa-2. KRAS-IN-51 can be used for research on colorectal cancer and pancreatic cancer.
-
SOS1-IN-4
0 ImagesCat. No.: HY-145047CAS No.: 2738392-83-9SOS1-IN-4 is a potent SOS1 inhibitor with an IC50 of 56 nM for KRAS-C12C/SOS1 interaction (WO2021228028 A1, example 65).
-
KRAS G12C inhibitor 50
0 ImagesCat. No.: HY-147631CAS No.: 2760354-12-7KRAS G12C inhibitor 50 (Example 4) is a KRAS G12C inhibitor with an IC50 of 46.7 nM.
-
(7R/S)-Zecdarasib
0 ImagesCat. No.: HY-172626CAS No.: 2923669-28-5(7R/S)-Zecdarasib is a KRASG12D inhibitor. (7R/S)-Zecdarasib can be used in the cancer research.
-
KRAS G12C inhibitor 55
0 ImagesCat. No.: HY-147636CAS No.: 2508134-76-5KRAS G12C inhibitor 55 (Compound 1) is a KRAS G12C inhibitor.
-
KRAS G12C inhibitor 51
0 ImagesCat. No.: HY-147632CAS No.: 2762632-78-8KRAS G12C inhibitor 51 (example 1) is a KRAS G12C inhibitor.
-
SML-8-73-1
0 ImagesCat. No.: HY-19315CAS No.: 1536470-92-4SML-8-73-1 is a nucleotide-based KRASG12C inhibitor. SML-8-73-1 can be used for the study of non-small cell lung cancer (NSCLC).
-
MRTX849 ethoxypropanoic acid
0 ImagesCat. No.: HY-139403CAS No.: 2561529-98-2
-
RP04340
0 ImagesCat. No.: HY-189222CAS No.: 3118096-98-0RP04340 is an orally active, selective pan-KRAS PROTAC degrader. RP04340 hijacks the CRBN E3 ligase and the cellular proteasome system to degrade KRAS, without degrading HRAS, NRAS, or common CRBN neosubstrates. RP04340 inhibits KRAS downstream signaling pathways, including pERK and DUSP6. RP04340 exhibits anticancer activity in various KRAS-mutant cancers. RP04340 can be used to study kras-driven cancers, including pancreatic ductal adenocarcinoma, colorectal cancer, and lung adenocarcinoma.
-
KRASG12D-IN-7
0 ImagesCat. No.: HY-175529KRASG12D-IN-7 is a selective KRASG12D inhibitor. KRASG12D-IN-7 displays strong binding activity for KRASG12D in both its GDP- and GTP- bound states, with Kd value of 1.12 nM and 1.86 nM, respectively. KRASG12D-IN-7 inhibits the proliferation of KRASG12D harboring AsPC-1 cells with an IC50 value of 10 nM and suppresses MAPK signaling. KRASG12D-IN-7 induces G0/G1 phase arrest and apoptosis in AsPC-1 cells, and strongly inhibits their colony formation. KRASG12D-IN-7 can be used for the study of cancers harboring KRASG12D mutation, particularly pancreatic ductal adenocarcinoma (PDAC).
-
YN14-H
0 ImagesCat. No.: HY-173250YN14-H is a potent mutant KRASG12C PROTAC degrader. The DC50 values of YN14-H in NCI-H358 and MIA PaCa-2 cells are 28.9 nM and 18.1 nM, respectively, with corresponding IC50 values of 42 nM and 21 nM. YN14-H degrades KRASG12C in a ubiquitin-proteasome system-dependent manner, thereby significantly inducing apoptosis and inhibiting cell migration. YN14-H can be used for targeting tumors with KRASG12C mutations (such as non-small cell lung cancer, pancreatic cancer, etc.).
-
(4S)-PROTAC SOS1 degrader-1
0 ImagesCat. No.: HY-144657CAS No.: 2913176-81-3(4S)-PROTAC SOS1 degrader-1 is a stereoisomer of PROTAC SOS1 degrader-1 (HY-145737). PROTAC SOS1 degrader-1 (Compound 9d) is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 can be used for the research of KRAS-driven cancers.
-
KRAS-IN-62
0 ImagesCat. No.: HY-187520CAS No.: 3137385-11-3KRAS-IN-62 is an orally effective pan-KRAS inhibitor that potently inhibits SOS1-mediated KRAS nucleotide exchange (IC50 < 10 nM for KRAS G12D/G12V/G12C/WT). KRAS-IN-62 inhibits pERK signaling and cell proliferation in KRAS-mutant tumor cells (pERK IC90 = 0.51 nM in GP2D cells). KRAS-IN-62 inhibits tumor growth in vivo, with plasma concentrations exceeding IC50 for ~20 h after oral administration in beagle dogs. KRAS-IN-62 can be used in studies of KRAS mutation-related cancers, such as colorectal cancer.
-
KRas G12C inhibitor 3
0 ImagesCat. No.: HY-112493CAS No.: 2206735-75-1KRas G12C inhibitor 3 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
-
PROTAC K-Ras Degrader-6
0 ImagesCat. No.: HY-168678CAS No.: 3052745-46-4PROTAC K-Ras Degrader-6 (compound 102) is a potent cereblon-based KRAS PROTAC degrader, with a DC50 of ≤100 nM. PROTAC K-Ras Degrader-6 shows anticancer effects.
-
KRAS G12C inhibitor 68
0 ImagesCat. No.: HY-159611CAS No.: 3034851-27-6KRAS G12C inhibitor 68 (compound I-063) is a KRAS G12C inhibitor with an IC50 of 7 nM. KRAS G12C inhibitor 68 has anti-tumor activity.
